Cytosorbents CTSO was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract valued at up to $2.9 million over a two-year period, enabling CTSO to move HemoDefend-BGA closer to commercialization. We believe the new contract validates the potential of the HemoDefend technology. Moreover, it continues the company's successful strategy of pursuing and winning grant income to help subsidize R&D spending.